Germany-based Grünenthal Group has reported the successful completion of a Phase I trial for its proprietary nociceptin receptor (NOP) agonist, an investigational pain compound targeting a G protein-coupled receptor pathway that is mechanistically distinct from classical opioid signaling. The trial enrolled 113 healthy participants and demonstrated a safety and tolerability profile that the company says supports progression into Phase II, with no dose-dependent adverse event pattern observed and no signals of abuse liability or opioid-associated side effects such as somnolence, constipation, or respiratory depression. The compound has yet to be named publicly.
The resultadvances what Grünenthal is positioning as a potential first-in-class pain therapy into efficacy testing at a moment when the non-opioid analgesic landscape is becoming increasingly competitive. Vertex Pharmaceuticals' Journavx (suzetrigine) received US FDA approval in January 2025 for moderate-to-severe acute pain — the first novel systemic non-opioid analgesic approved in roughly 25 years — and Tris Pharma's cebranopadol, a dual NOP/mu-opioid receptor (MOP) agonist, has now reported positive Phase III data in both bunionectomy and abdominoplasty models. Grünenthal's program, by contrast, targets the NOP receptor selectively without MOP co-activation, a pharmacological distinction that could yield a cleaner abuse-liability profile but will need to demonstrate comparable efficacy in controlled trials.
Grünenthal first enrolled participants in this first-in-human study in October 2024, at that point projecting results by Q3 2025. The now-completed trial covered single and multiple ascending dose cohorts, with the primary objective of characterizing safety, tolerability, and pharmacokinetics.
The Phase II trial, planned to commence later in 2026, will enroll approximately 400 US-based patients undergoing bunionectomy — a surgical procedure that regulatory authorities accept as a validated hard-tissue postoperative pain model for acute analgesic evaluation. Results are expected in the second half of 2027. The bunionectomy model is well-established in this space, the basis of key pivotal trials for both suzetrigine and for Tris Pharma's cebranopadol. The shared model will at least allow Grünenthal's Phase II to be evaluated against a well-characterized regulatory benchmark.
The NOP receptor is a G protein-coupled receptor whose endogenous ligand is the 17-amino-acid neuropeptide nociceptin. Although the NOP receptor shares approximately 60% sequence identity with the classical opioid receptors (mu, kappa, delta), it has little affinity for opioid peptides or morphine-like compounds, and opioid receptors in turn show minimal affinity for nociceptin. This pharmacological separation is the basis for preclinical evidence suggesting NOP agonists can produce analgesia without the abuse liability associated with MOP activation.